B. Riley analyst Bryan Maher lowered the firm’s price target on Alerislife to $1.50 from $2 and keeps a Neutral rating on the shares following the "mixed" Q3 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALR: